Explore the vast range of titles available.

In this trial involving patients at increased risk for pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP), rectal indomethacin reduced the incidence of this condition, as compared with placebo (9% vs. 17%). Acute pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP), 1 accounting for substantial morbidity, occasional death, and estimated health care expenditures of approximately $150 million annually in the United States. 2 , 3 Given the magnitude of this problem, more than 35 pharmacologic agents have been studied for the prophylaxis of post-ERCP pancreatitis, and many prospective clinical trials addressing chemoprevention have been conducted. To date, however, no medication has proved to be consistently effective in preventing post-ERCP pancreatitis on the basis of data from high-quality clinical trials, and no pharmacologic prophylaxis for post-ERCP pancreatitis is in widespread clinical use. . . .